Institut Curie, PSL Research University, CNRS UMR 3348, Orsay, France.
Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, Orsay, France.
Clin Cancer Res. 2017 Jan 1;23(1):21-25. doi: 10.1158/1078-0432.CCR-14-2362. Epub 2016 Oct 27.
The eIF4F complex regulates the cap-dependent mRNA translation process. It is becoming increasingly evident that aberrant activity of this complex is observed in many cancers, leading to the selective synthesis of proteins involved in tumor growth and metastasis. The selective translation of cellular mRNAs controlled by this complex also contributes to resistance to cancer treatments, and downregulation of the eIF4F complex components can restore sensitivity to various cancer therapies. Here, we review the contribution of the eIF4F complex to tumorigenesis, with a focus on its role in chemoresistance as well as the promising use of new small-molecule inhibitors of the complex, including flavaglines/rocaglates, hippuristanol, and pateamine A. Clin Cancer Res; 23(1); 21-25. ©2016 AACR.
真核起始因子 4F 复合物调节帽依赖的 mRNA 翻译过程。越来越多的证据表明，该复合物的异常活性存在于许多癌症中，导致与肿瘤生长和转移相关的蛋白质的选择性合成。该复合物控制的细胞 mRNA 的选择性翻译也有助于对癌症治疗的耐药性，下调真核起始因子 4F 复合物的组成部分可以恢复对各种癌症治疗的敏感性。在这里，我们综述了真核起始因子 4F 复合物在肿瘤发生中的作用，重点介绍了它在化疗耐药中的作用以及该复合物的新型小分子抑制剂的有前途的应用，包括 flavaglines/rocaglates、 hippuristanol 和 pateamine A。临床癌症研究; 23(1); 21-25。©2016AACR。
